Calithera Biosciences Inc. didn't have to dig deep to expand its pipeline of cancer drugs, taking an exclusive global license to a portfolio of hexokinase II inhibitors developed by Transtech Pharma LLC (TTP) and affiliate High Point Pharmaceuticals LLC for a mere $600,000 up front. Calithera, of South San Francisco, will owe development and regulatory milestone payments of up to $30.5 million for the first licensed product, and Transtech is eligible for up to $77 million in sales-based milestones, plus mid-single-digit royalty payments, on tiered sales of the first commercialized product.